SEARCH OUR PAGES

Investors

Investors

Publications & information

Press Releases

Read more +

Corporate Presentation

Read more +

Regulated Information

Read more +

General Shareholders' Meetings

Read more +

Financial Statements

Reference document
Semester Financial report

Read more +

Live stock price

Click here for live stock price

Information

OSE Immunotherapeutics is listed since 30th March 2015 on the regulated market of Euronext Paris

  • ISIN: FR0012127173
  • Ticker: OSE
  • Type of listing: continuous
  • Number of outstanding shares: 14,374,970 shares as of December 31, 2017
  • Eligible to Long-Only Deferred Settlement Service

Financial agenda

28 March 2019 Publication of the 2018 consolidated accounts
26 June 2019 Annual General Meeting
5 September 2019 Publication of 2019 half-year results

Press releases are distributed after the close of the stock market.
This financial calendar is for indicative purposes only and OSE Immunotherapeutics could change its publication dates should it deem it necessary.

Analysts following OSE Immunotherapeutic

  • H.C. Wainwright & CO. (US) Swayampakula Ramakanth

    E-MAIL
  • LifeSci Capital (US) Jacques Villefranc

    E-MAIL
  • Edison (UK) Jonas Peciulis

    E-MAIL
  • Kepler Cheuvreux (FR) Thomas Guillot

    E-MAIL
  • Invest Securities (FR) Martial Descoutures

    E-MAIL
  • Portzamparc (FR) Christophe Dombu

    E-MAIL

Analyst Reports

2018

2017

2016

Any opinions, estimates or forecasts regarding OSE Immunotherapeutics performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of OSE Immunotherapeutics or its management.

Subscribe to our press releases


SUBMIT

You confirm that you have read our privacy policy. You can unsubscribe at any time by using the unsubscribe links or by contacting us at contact@ose-immuno.com